Search

Your search keyword '"Chatterjee, Debashree"' showing total 148 results

Search Constraints

Start Over You searched for: Author "Chatterjee, Debashree" Remove constraint Author: "Chatterjee, Debashree"
148 results on '"Chatterjee, Debashree"'

Search Results

2. Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity

3. Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD

5. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

6. Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients

7. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection

8. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

10. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis

11. NTB-A and 2B4 Natural Killer Cell Receptors Modulate the Capacity of a Cocktail of Non-Neutralizing Antibodies and a Small CD4-Mimetic to Eliminate HIV-1-Infected Cells by Antibody-Dependent Cellular Cytotoxicity.

13. Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV

15. Identification of Aryl Hydrocarbon Receptor as a Barrier to HIV-1 Infection and Outgrowth in CD4+ T-Cells (C. Van Lint and P. Ancuta are co-corresponding authors)

16. A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile

18. Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine

22. SARS-CoV-2 Omicron subvariants Spike recognition and neutralization elicited after the third dose of mRNA vaccine

23. COVID ‐19 vaccine humoral response in frequent platelet donors with plateletpheresis‐associated lymphopenia

24. Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity

25. SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses

26. Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients

27. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

28. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes

29. SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses

30. Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth

31. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

32. An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice

33. Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study

35. Contribution of single mutations to selected SARS-CoV-2 emerging variants Spike antigenicity

37. Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study

38. Pharmacological Inhibition of PPARy Boosts HIV Reactivation and Th17 Effector Functions, while Preventing Progeny Virion Release and de novo Infection

39. Daily variations of gut microbial translocation markers in ART-treated HIV-infected people

49. Identification of aryl hydrocarbon receptor as a barrier to HIV-1 infection and outgrowth in CD4+T cells

Catalog

Books, media, physical & digital resources